# Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)

> **NCT05787444** · — · UNKNOWN · sponsor: **LumiraDx UK Limited** · enrollment: 1500 (estimated)

## Conditions studied

- SARS-CoV-2
- Influenza A
- Influenza B
- Asymptomatic COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** LumiraDx SARS-CoV-2 & Flu A/B

## Key facts

- **NCT ID:** NCT05787444
- **Lead sponsor:** LumiraDx UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-20
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787444, "Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05787444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*